Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 442 across all filing types
Latest filing 2024-04-24 Regulatory Filings
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
IMMUPHARMA AT BIO-EQUITY 2024 12-14 May
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 7666L' and explicitly mentions 'RNS REACH | 24 April 2024'. The content describes the company's CEO and COO attending the BIO-Equity partnering event to discuss potential global partnering deals for their pipeline portfolio. The 'Notes to Editors' section explicitly defines Reach announcements as 'non-regulatory news releases such as marketing messages, corporate and product information into the public domain.' This content is an announcement about management attending a conference for business development, which is not a core financial report (like 10-K, IR, ER) or a specific regulatory filing (like DIRS, DIV, SHA). Since it is a non-regulatory announcement distributed via the RNS system, the most appropriate classification is 'Regulatory Filings' (RNS) as the general category for miscellaneous regulatory/market communications that don't fit the highly specific categories, or potentially a general announcement if RNS is interpreted strictly as regulatory filings only. Given the context that RNS is the fallback for miscellaneous filings and this is a standard RNS distribution format for non-regulatory news, RNS is the best fit among the provided options for a general market update distributed through this channel.
2024-04-24 English
Grant of Share Options
Remuneration Information Classification · 1% confidence The document is an official announcement released via RNS (London Stock Exchange's news service) on April 19, 2024. The content explicitly details the 'Grant of Share Options' to directors (Lisa Baderoon and Laurence Reilly) and includes mandatory regulatory disclosure tables regarding 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. This type of transaction reporting, specifically involving insider trades or executive share dealings, maps directly to the 'Director's Dealing' category. While it is an RNS filing, the specific nature of the content (director option grants/trades) makes 'DIRS' a more precise classification than the general 'RNS' fallback.
2024-04-19 English
New intellectual property strategy initiated
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 9109I' and contains standard boilerplate language indicating it is distributed via RNS, the news service of the London Stock Exchange, and mentions compliance with Market Abuse Regulation. The content announces a strategic update ('New intellectual property strategy initiated') by ImmuPharma PLC. This type of announcement, which is a general corporate update disseminated through an official regulatory news service (RNS) and does not fit into specific categories like Earnings Release (ER), Director's Dealing (DIRS), or Capital Change (SHA), is best classified as a general Regulatory Filing or announcement. Since RNS is explicitly mentioned as the distribution service and the content is a material, non-financial-specific update, the most appropriate code is RNS, the general regulatory announcement fallback.
2024-04-02 English
Incanthera provides Comm'l Update/Revenue F'casts
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and contains standard boilerplate language from RNS (Regulatory News Service) of the London Stock Exchange, including the disclaimer at the end. The content itself is an announcement by ImmuPharma PLC highlighting a commercial update and revenue forecasts from Incanthera plc, in which ImmuPharma holds a significant share. This type of announcement, which relays news from another listed entity or provides general operational updates via the official regulatory news wire, fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (10-K, IR, ER), a management discussion (MDA), or a director dealing report (DIRS). Given the source (RNS) and the nature of relaying market-sensitive information that doesn't fit a more specific code, RNS is the appropriate classification.
2024-03-25 English
Grant of Share Options
Remuneration Information Classification · 1% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement from the London Stock Exchange, indicated by the 'RNS Number' and the concluding boilerplate text mentioning RNS and the FCA. The content details the 'Grant of Share Options' to executive directors and employees, which is a form of insider transaction/remuneration disclosure. While it involves directors' dealings (DIRS) and remuneration (DEF 14A), the primary nature of this specific filing format—a mandatory, immediate regulatory disclosure via RNS—makes the most appropriate classification the general regulatory announcement category, RNS, especially since it is not a full annual report (10-K), a formal proxy statement (DEF 14A), or a detailed director's dealing report (DIRS) which often have specific SEC form numbers. Given the structure and source (LSE RNS), RNS is the best fit for this type of immediate regulatory update.
2024-03-19 English
IMMUPHARMA AT BIO-EUROPE SPRING 2024
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and contains a date (14 March 2024) and company information (Immupharma PLC). The content announces that company executives will be attending the BIO-Europe Spring event to present their portfolio and seek partnering opportunities. The document explicitly mentions 'Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain.' This strongly indicates a general, non-mandatory regulatory announcement or marketing update. Since it is not a specific financial report (like 10-K, IR, ER) or a specific corporate action (like DIV, CAP, DIRS), and it is distributed via RNS, the most appropriate classification is 'Regulatory Filings' (RNS), which serves as the general category for such announcements.
2024-03-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.